1,882 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Summit Trail Advisors LLC

Summit Trail Advisors LLC acquired a new stake in shares of Insulet Co. (NASDAQ:PODD - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 1,882 shares of the medical instruments supplier's stock, valued at approximately $491,000.

A number of other hedge funds have also made changes to their positions in PODD. Baillie Gifford & Co. boosted its stake in Insulet by 20.7% in the 3rd quarter. Baillie Gifford & Co. now owns 2,275,701 shares of the medical instruments supplier's stock worth $529,669,000 after purchasing an additional 389,639 shares during the period. Geode Capital Management LLC boosted its stake in Insulet by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,738,601 shares of the medical instruments supplier's stock worth $403,339,000 after purchasing an additional 22,850 shares during the period. Westfield Capital Management Co. LP boosted its stake in Insulet by 27.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 754,872 shares of the medical instruments supplier's stock worth $175,697,000 after purchasing an additional 163,388 shares during the period. Charles Schwab Investment Management Inc. boosted its stake in Insulet by 43.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 636,265 shares of the medical instruments supplier's stock worth $148,091,000 after purchasing an additional 193,839 shares during the period. Finally, Fisher Asset Management LLC boosted its stake in Insulet by 0.9% in the 3rd quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier's stock worth $81,719,000 after purchasing an additional 3,113 shares during the period.

Insider Buying and Selling

In other news, CAO Lauren Budden sold 915 shares of the business's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the business's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. The trade was a 52.13 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.47% of the company's stock.

Insulet Stock Down 0.6 %

Shares of PODD stock traded down $1.56 on Friday, hitting $280.56. The company's stock had a trading volume of 474,733 shares, compared to its average volume of 522,338. The stock has a market capitalization of $19.68 billion, a price-to-earnings ratio of 48.04, a P/E/G ratio of 3.61 and a beta of 1.23. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm's fifty day moving average price is $271.74 and its 200-day moving average price is $244.38.

Analyst Ratings Changes

A number of equities research analysts have issued reports on PODD shares. Morgan Stanley lifted their target price on shares of Insulet from $234.00 to $317.00 and gave the company an "overweight" rating in a research note on Monday, November 11th. TD Cowen lifted their target price on shares of Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a research note on Friday, January 3rd. Canaccord Genuity Group lifted their target price on shares of Insulet from $269.00 to $304.00 and gave the company a "buy" rating in a research note on Monday, December 9th. Wells Fargo & Company lifted their target price on shares of Insulet from $290.00 to $305.00 and gave the company an "overweight" rating in a research note on Wednesday, December 11th. Finally, Barclays lifted their target price on shares of Insulet from $220.00 to $234.00 and gave the company an "equal weight" rating in a research note on Monday, November 11th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $277.13.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.